价格

Applied Therapeutics

ACTIVE

2259 NW Troost St, Roseburg, New York, 美国www.appliedtherapeutics.comPublic25 名员工

别名:

aplt.us

aplt

applied therapeutics, inc.

概览

试验阶段分布

阶段

试验数

占比

3 期

50.0%

2 期

33.3%

1 期

16.7%

试验状态分布

进行中（未招募）

16.7%

已完成

50.0%

Unknown

16.7%

撤回

16.7%

药物批准

暂无批准数据

资讯

BridgeBio's Attruby Approved for ATTR-CM, Cassava's Simufilam Fails in Alzheimer's Trial

- BridgeBio Pharma's Attruby (acoramidis) receives FDA approval for transthyretin amyloidosis cardiomyopathy (ATTR-CM), reducing cardiovascular death and hospitalization. - Cassava Sciences' simufilam fails to meet primary endpoints in a Phase III Alzheimer's disease trial, leading to discontinuation of further studies. - Amgen's MariTide demonstrates significant weight loss in Phase II study for obesity, with additional cardiometabolic benefits and manageable side effects. - Applied Therapeutics receives a Complete Response Letter from the FDA for govorestat in classic galactosemia due to deficiencies in clinical study results.

Nov 30, 2024

返回机构列表

Applied Therapeutics

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（6）

Confirmatory Study of Govorestat in CMT-SORD

Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency

AT-007 in Adult Subjects With Classic Galactosemia (CG)

Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia

药物批准

资讯

BridgeBio's Attruby Approved for ATTR-CM, Cassava's Simufilam Fails in Alzheimer's Trial